Changes in etanercept and adalimumab biosimilar prescriptions for the initial treatment of rheumatoid arthritis in France: Data from the ART-SFR Registry
Authors:
- Adeline Ruyssen-WitrandARAdeline Ruyssen-Witrand
- Yacine BoudaliYBYacine Boudali
- Isabelle PaneIPIsabelle Pane
- Alain CantagrelACAlain Cantagrel
- Pascale ThevenotPTPascale Thevenot
- Martin SoubrierMSMartin Soubrier
- Jacques MorelJMJacques Morel
- Eric HouvenagelEHEric Houvenagel
- Alain SarauxASAlain Saraux
- André BaschABAndré Basch
- Marie-Elise TruchetetMTMarie-Elise Truchetet
- Hubert MarotteHMHubert Marotte
- 1 May 2022
- journal article
- editorial
- Published by Elsevier in Joint Bone Spine
- Vol. 89 (3) , 105310
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Potential Cost Implications of Mandatory Non‐Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in CanadaClinical Pharmacology & Therapeutics, 2020
- Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)Seminars in Arthritis and Rheumatism, 2019
- To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registryAnnals of the Rheumatic Diseases, 2019
- Biosimilars in the management of chronic inflammatory diseases: The Dutch experienceMediterranean Journal of Rheumatology, 2019
- The confidence of rheumatologists about switching to biosimilars for their patientsJoint Bone Spine, 2018
- Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptanceJoint Bone Spine, 2018
- Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi PanelFrontiers in Pharmacology, 2017